Wide Open Agriculture cut its loss to $3.64 million in FY2026 as it pivots from owning manufacturing to a capital-light contract model, while securing global commercial traction for its lupin-based ingredients.
- Loss after tax reduced to $3.64 million from $6.89 million
- German manufacturing facility wound down post-year-end
- Transition to contract manufacturing targeting 500–1,000 tonnes annually
- Secured 8 customers and 30+ commercial product launches globally
- Expanded IP portfolio and received $1.69 million R&D tax rebate
Loss narrows amid strategic manufacturing pivot
Wide Open Agriculture (ASX:WOA) has trimmed its after-tax loss to $3.64 million for the year ended 30 June 2026, down from a $6.89 million loss the previous year. The company’s financials reflect a pivotal transition away from owner-operated manufacturing toward a capital-light contract manufacturing model aimed at improving unit economics and scalability.
Following a detailed review of its German manufacturing facility acquired in 2024, WOA decided to wind down operations there shortly after the financial year ended. The facility, while key to early commercial product validation and regulatory approvals, proved costly with negative operating margins due to rising energy and labour expenses and underutilised capacity.
Contract manufacturing strategy gains momentum
WOA’s new manufacturing strategy involves outsourcing production to third-party contract manufacturers, primarily in Asia, to better align capacity with customer demand and reduce fixed costs. The company has identified around 90 potential contract manufacturers, signed 12 non-disclosure agreements, and is negotiating multiple non-binding term sheets, setting a promising stage for future scale-up.
This shift targets an initial production scale of 500 to 1,000 tonnes per annum of lupin protein isolate, with flexibility to grow alongside commercial demand. The approach is designed to preserve cash while leveraging WOA’s proprietary technology, intellectual property, and commercial relationships.
Commercial progress and product diversification
On the commercial front, WOA secured eight customers and facilitated over 30 product launches globally during FY2026, spanning beverages, nutrition, and other food categories. The company advanced its partnership with Univar Solutions China, moving from market development toward commercial rollout, though further expansion was tempered by the manufacturing transition.
WOA also progressed its whole-of-seed product model, achieving initial sales of lupin oil in the cosmetics sector and advancing lupin fibre development. These additional product streams aim to enhance revenue and margins by extracting more value from each tonne of lupin processed, aligning with sustainability goals.
IP expansion and R&D support liquidity
The company bolstered its intellectual property portfolio by filing a patent for a novel lupin protein milk formulation targeting beverage applications. It also secured improved royalty terms with Curtin University, streamlining future commercialisation economics.
WOA’s R&D efforts continued to focus on refining production processes to improve efficiency and product functionality. The company received approximately $1.69 million in R&D tax incentive rebates during the year, providing a meaningful boost to liquidity.
Leadership refresh and disciplined capital allocation
FY2026 saw significant leadership changes with the appointment of Craig Swan as CEO and Justin Brown as Chair, bringing deep food ingredient and capital markets experience respectively. The board was further strengthened with new non-executive directors, while some founding members departed.
Looking ahead, WOA plans to maintain tight capital discipline, limiting near-term marketing and R&D spend and deferring some board and executive fees. Investment will be closely tied to customer demand and improving manufacturing economics, with a long-term goal of establishing a large-scale lupin ingredient facility in Western Australia pending favorable market conditions.
Bottom Line?
WOA’s pivot to contract manufacturing and commercial progress position it for more sustainable growth, but execution risks remain as it scales production and converts pipeline opportunities.
Questions in the middle?
- How quickly can WOA convert its growing customer pipeline into sustained sales under the new manufacturing model?
- What impact will the wind-down of the German facility have on short-term supply continuity and customer relationships?
- Will the planned large-scale Australian lupin facility gain traction amid evolving demand and capital constraints?